Helping Apo2L/TRAIL in the Battle: Synergistic Therapeutic Approaches for Cancer Therapies
International Journal of Molecular Sciences · 07.08.2026 · 27 (16) · 7068
DOI: 10.3390/ijms27167068 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 07.08.2026. Verfasst von Elena Valeria Fuior und 15 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Cellular Biology and Pathology "Nicolae Simionescu", Romanian Academy, 050568 Bucharest, Romania. Hauptthemen laut MEDLINE: TNF-Related Apoptosis-Inducing Ligand, Neoplasms. Die Arbeit nennt 220 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union (NextGenerationEU).
Abstract (Originalsprache)
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) selectively triggers apoptosis in malignant, infected, or stressed cells while sparing normal tissues, making it an attractive therapeutic candidate. However, many tumors exhibit intrinsic or acquired resistance to TRAIL, driven by reduced DR4/DR5 surface expression, elevated decoy receptor levels, dysregulated DISC assembly, overexpression of c-FLIP and anti-apoptotic Bcl-2 family proteins, or activation of survival pathways such as NF-κB, PI3K/Akt, and MAPK. Moreover, TRAIL receptors can initiate non-canonical signaling pathways that promote migration, invasion, and metastasis in specific oncogenic contexts, thereby further limiting therapeutic efficacy. We aimed to integrate mechanistic insights into TRAIL biology with current therapeutic advances, providing a comprehensive framework for understanding resistance and for designing rational TRAIL-based combination strategies. We summarized the structural and signaling features of TRAIL receptors, outlined the major determinants of TRAIL sensitivity, and evaluated predictive biomarkers that may guide patient selection. In addition, we examined next-generation TRAIL agonists and targeted delivery systems developed to enhance receptor clustering, pharmacokinetics, and tumor specificity. Together, these insights highlight the therapeutic promise of mechanistically informed TRAIL combinations. A deeper understanding of resistance pathways and biomarker-guided stratification will be essential for restoring apoptotic competence and improving clinical outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Cellular Biology and Pathology "Nicolae Simionescu", Romanian Academy, 050568 Bucharest, Romania.
- Neurosurgery Clinic, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.
- Department of Neurosurgery, Bagdasar-Arseni Emergency Clinical Hospital, 041915 Bucharest, Romania.
- Pharmacology Laboratory, Department of Medicine, University of Patras, 26504 Rio Achaias, Greece.
ORCID-Profile: Elena Valeria Fuior, Marius Gabriel Multescu, Madalin Ghinea, George E D Petrescu, Ana Maria Vacaru, Radu Ionita, Ioana Madalina Fenyo, Evangelia Zvintzou, Anca Violeta Gafencu
Förderung
- European Union (NextGenerationEU)
Zitieren
APA
Fuior, E. V., Dumitrescu, M., Multescu, M. G., Daraban, B. S., Ghinea, M., Mirancea, O., Petrescu, G. E. D., Brehar, F. M., Vacaru, A. M., Ionita, R., Bivol, V. G., Tudorache, I. F., Popa, A., Fenyo, I. M., Zvintzou, E., & Gafencu, A. V. (2026). Helping Apo2L/TRAIL in the Battle: Synergistic Therapeutic Approaches for Cancer Therapies. International Journal of Molecular Sciences, 27(16), 7068. https://doi.org/10.3390/ijms27167068
Vancouver
Fuior EV, Dumitrescu M, Multescu MG, Daraban BS, Ghinea M, Mirancea O, et al. Helping Apo2L/TRAIL in the Battle: Synergistic Therapeutic Approaches for Cancer Therapies. International Journal of Molecular Sciences. 2026;27(16):7068. doi:10.3390/ijms27167068
BibTeX
@article{Fuior2026,
author = {Fuior, Elena Valeria and Dumitrescu, Madalina and Multescu, Marius Gabriel and Daraban, Bianca Sanziana and Ghinea, Madalin and Mirancea, Oana and Petrescu, George E D and Brehar, Felix Mircea and Vacaru, Ana Maria and Ionita, Radu and Bivol, Violeta Georgeta and Tudorache, Irina Florina and Popa, Andreea and Fenyo, Ioana Madalina and Zvintzou, Evangelia and Gafencu, Anca Violeta},
title = {Helping Apo2L/TRAIL in the Battle: Synergistic Therapeutic Approaches for Cancer Therapies},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {16},
pages = {7068},
doi = {10.3390/ijms27167068}
}
EUVIMED